<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378999</url>
  </required_header>
  <id_info>
    <org_study_id>METC17-3-026</org_study_id>
    <nct_id>NCT03378999</nct_id>
  </id_info>
  <brief_title>Rhodospirillum Rubrum and Cholesterol</brief_title>
  <official_title>A Proof of Concept Study to Demonstrate a Cholesterol-lowering Benefit of Oven-dried Rhodospirillum Rubrum</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>ezCOL B.V.</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Maastricht University Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to examine for the first time the LDL cholesterol&#xD;
      lowering effect of oven-dried Rhodospirillum rubrum in humans.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objectives:&#xD;
&#xD;
      Secondary objectives are to investigate the effects on other CVD risk parameters: total&#xD;
      cholesterol, triacylglycerol, HDL-C, glucose and blood pressure. Safety will be monitored by&#xD;
      measurements of markers for liver, kidney and heart function.&#xD;
&#xD;
      Study design:&#xD;
&#xD;
      The study is a 4-weeks randomized, double-blind placebo-controlled trial with a parallel&#xD;
      design using 3 doses oven-dried Rhodospirillum rubrum. Prior to and after the intervention&#xD;
      period, a 2-week run-in and run-out period takes place, during which all subjects will&#xD;
      consume placebo capsules.&#xD;
&#xD;
      Study population:&#xD;
&#xD;
      Eighty (N=80) healthy men with a slightly elevated fasting serum total cholesterol&#xD;
      concentration (between 5.0-8.0 mmol/l) will complete the study.&#xD;
&#xD;
      Intervention:&#xD;
&#xD;
      During the intervention period of 4 weeks, men will receive either placebo or capsules&#xD;
      containing 0.25 gr, 0.5 gr or 1.0 gr oven-dried Rhodospirillum rubrum per day.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 14, 2018</start_date>
  <completion_date type="Actual">May 10, 2019</completion_date>
  <primary_completion_date type="Actual">May 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>LDL cholesterol concentrations</measure>
    <time_frame>Change from baseline LDL cholesterol concentrations at 4 weeks</time_frame>
    <description>Fasting LDL cholesterol concentrations will be determined in blood samples using the Friedewald equation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Markers for fasting lipid metabolism</measure>
    <time_frame>Change from baseline concentrations at 4 weeks</time_frame>
    <description>Markers for fasting lipid metabolism include serum total cholesterol (mmol/L), HDL cholesterol (mmol/L), and triacylglycerol concentrations (mmol/L).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Glucose concentrations</measure>
    <time_frame>Change from baseline concentrations at 4 weeks</time_frame>
    <description>Fasting plasma glucose concentrations will determined in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blood pressure</measure>
    <time_frame>Change from baseline blood pressure at 4 weeks</time_frame>
    <description>Systolic and diastolic blood pressure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>C-reactive protein</measure>
    <time_frame>hs-CRP will be will be measured at day 0, day 14, day 25 and day 28 of the intervention period</time_frame>
    <description>Concentrations of hs-CRP will be determined in blood samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for liver function</measure>
    <time_frame>These markers will be measured at day 0, day 14, day 25 and day 28 of the intervention period</time_frame>
    <description>Markers for liver function include ALAT, ASAT and yGT (U/L). This panel of markers will be assessed to monitor liver function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for kidney function</measure>
    <time_frame>These markers will be measured at day 0, day 14, day 25 and day 28 of the intervention period</time_frame>
    <description>Markers for kidney function include creatinine</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for heart function (NT-ProBNP)</measure>
    <time_frame>These markers will be measured at day 0, day 14, day 25 and day 28 of the intervention period</time_frame>
    <description>Markers for heart function include NT-ProBNP. This panel of markers will be assessed to monitor heart function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for heart function (vWF)</measure>
    <time_frame>These markers will be measured at day 0, day 14, day 25 and day 28 of the intervention period</time_frame>
    <description>Markers for heart function include vWF. This panel of markers will be assessed to monitor heart function.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Markers for heart function (Troponin-T)</measure>
    <time_frame>These markers will be measured at day 0, day 14, day 25 and day 28 of the intervention period</time_frame>
    <description>Markers for heart function include Troponin-T. This panel of markers will be assessed to monitor heart function.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">82</enrollment>
  <condition>Cholesterol Metabolism</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo capsules containing microcrystalline cellulose</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhodospirillum rubrum 0.25 gram/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing oven-dried Rhodospirillum rubrum, 0.25 gram/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhodospirillum rubrum 0.5 gram/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing oven-dried Rhodospirillum rubrum, 0.5 gram/day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rhodospirillum rubrum 1.0 gram/day</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Capsules containing oven-dried Rhodospirillum rubrum, 1.0 gram/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Rhodospirillum rubrum</intervention_name>
    <description>Capsules containing oven-dried Rhodospirillum rubrum</description>
    <arm_group_label>Rhodospirillum rubrum 0.25 gram/day</arm_group_label>
    <arm_group_label>Rhodospirillum rubrum 0.5 gram/day</arm_group_label>
    <arm_group_label>Rhodospirillum rubrum 1.0 gram/day</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Control</intervention_name>
    <description>Capsules containing microcrystalline cellulose</description>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Minimum 80 kg body weight;&#xD;
&#xD;
          -  Serum total cholesterol between 5.0 - 8.0 mmol/L (further testing is recommended for&#xD;
             excessive hyperlipidemia [serum total cholesterol â‰¥ 8.0 mmol/L] according to the&#xD;
             Standard for cardiovascular risk management of the Dutch general practitioners&#xD;
             community [NHG]);&#xD;
&#xD;
          -  Serum triacylglycerol concentrations &lt; 4.5 mmol/L;&#xD;
&#xD;
          -  No signs of liver and/or kidney dysfunction;&#xD;
&#xD;
          -  No diabetic patients;&#xD;
&#xD;
          -  No familial hypercholesterolemia;&#xD;
&#xD;
          -  No abuse of drugs;&#xD;
&#xD;
          -  Not more than 4 alcoholic consumption per day with a maximum of 21 per week;&#xD;
&#xD;
          -  Stable body weight (weight gain or loss &lt; 3 kg in the past three months);&#xD;
&#xD;
          -  No use of medication known to treat blood pressure, lipid or glucose metabolism;&#xD;
&#xD;
          -  No use of an investigational product within another biomedical intervention trial&#xD;
             within the previous 1-month;&#xD;
&#xD;
          -  No severe medical conditions that might interfere with the study, such as epilepsy,&#xD;
             asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease,&#xD;
             inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis;&#xD;
&#xD;
          -  No active cardiovascular disease like congestive heart failure or cardiovascular&#xD;
             event, such as an acute myocardial infarction or cerebrovascular accident;&#xD;
&#xD;
          -  Willingness to give up being a blood donor from 8 weeks before the start of the study,&#xD;
             during the study and for 4 weeks after completion of the study;&#xD;
&#xD;
          -  No difficult venipuncture as evidenced during the screening visit;&#xD;
&#xD;
          -  Willing to comply to study protocol during study;&#xD;
&#xD;
          -  Informed consent signed.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Serum total cholesterol &lt; 5.0 mmol/L or â‰¥ 8.0 mmol/L;&#xD;
&#xD;
          -  Serum triacylglycerol concentrations â‰¥ 4.5 mmol/L;&#xD;
&#xD;
          -  Signs of liver and/or kidney dysfunction;&#xD;
&#xD;
          -  Diabetic patients;&#xD;
&#xD;
          -  Familial hypercholesterolemia;&#xD;
&#xD;
          -  Abuse of drugs;&#xD;
&#xD;
          -  More than 4 alcoholic consumptions per day or 21 per week;&#xD;
&#xD;
          -  Unstable body weight (weight gain or loss &gt; 3 kg in the past three months);&#xD;
&#xD;
          -  Use medication known to treat blood pressure, lipid or glucose metabolism;&#xD;
&#xD;
          -  Use of an investigational product within another biomedical intervention trial within&#xD;
             the previous 1-month;&#xD;
&#xD;
          -  Severe medical conditions that might interfere with the study, such as epilepsy,&#xD;
             asthma, kidney failure or renal insufficiency, chronic obstructive pulmonary disease,&#xD;
             inflammatory bowel diseases, auto inflammatory diseases and rheumatoid arthritis;&#xD;
&#xD;
          -  Active cardiovascular disease like congestive heart failure or cardiovascular event,&#xD;
             such as an acute myocardial infarction or cerebrovascular accident;&#xD;
&#xD;
          -  Not willing to give up being a blood donor from 8 weeks before the start of the study,&#xD;
             during the study or for 4 weeks after completion of the study;&#xD;
&#xD;
          -  Not or difficult to venipuncture as evidenced during the screening visit;&#xD;
&#xD;
          -  Use of over-the-counter and prescribed medication or supplements, which may interfere&#xD;
             with study measurements to be judged by the principal investigator;&#xD;
&#xD;
          -  Use of oral antibiotics in 40 days or less prior to the start of the study;&#xD;
&#xD;
          -  Blood donation in the past 3 months before the start of the study;&#xD;
&#xD;
          -  Not willing to comply to study protocol during study or sign informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jogchum Plat, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>Maastricht University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Maastricht University Medical Center</name>
      <address>
        <city>Maastricht</city>
        <state>Limburg</state>
        <zip>6229 ER</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>December 6, 2017</study_first_submitted>
  <study_first_submitted_qc>December 15, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 20, 2017</study_first_posted>
  <last_update_submitted>May 23, 2019</last_update_submitted>
  <last_update_submitted_qc>May 23, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">May 24, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

